Our Passion, Your Health.

Recent

8 May 2017

HYMOVIS®: An Innovation In Ha-Based Viscoelastic Hydrogel Technology In The Treatment Of Osteoarthritis Knee Pain

PARSIPPANY, NJ, May 8, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) - based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May

22 March 2017

HYMOVIS® Demonstrates Superior Biomechanical Lubricating Properties

HYMOVIS® has exceptional lubricating properties in moving cartilage to a low-friction regime. The study provides a unifying framework to evaluate the potential clinical efficacy of injectable hyaluronic acid therapies.
PARSIPPANY, NJ., March 22, 2017 - Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA) - based products and its

10 November 2016

HYMOVIS® Receives Permanent, Product-Specific J-Code from the Centers for Medicare and Medicaid Services (CMS)

PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services ("CMS") has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System ("HCPCS") code, or J-Code.

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness